Legend Biotech
LEGN
192 hedge funds and large institutions have $4.85B invested in Legend Biotech in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 88 increasing their positions, 59 reducing their positions, and 38 closing their positions.
88% more call options, than puts
Call options by funds: $75.2M | Put options by funds: $40M
49% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 59
8% more capital inflows, than outflows
Capital inflows: $550M | Capital outflows: $508M
0.47% more ownership
Funds ownership: 47.1% → 47.57% (+0.47%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
7% less funds holding
Funds holding: 206 → 192 (-14)
32% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$202M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$59M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$41.1M |
| 4 |
RA Capital Management
Boston,
Massachusetts
|
+$36M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital Holdings
London,
United Kingdom
|
-$73.2M |
| 2 |
Holocene Advisors
New York
|
-$60.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$37M |
| 4 |
Morgan Stanley
New York
|
-$33.1M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$27.5M |
LEGN Hedge Fund Activity: Q1 2024 in Review
192 of the 6,963 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q1 2024, worth a combined $4.85B — down 6% from $5.16B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of LEGN and 26 opened new positions — a net loss of 12 holders — while 59 trimmed existing stakes and 88 added.
The largest buyer was Fidelity Investments, adding an estimated $202M. The largest seller was Polar Capital Holdings, cutting an estimated $73.2M.
- 192 institutional investors held Legend Biotech (LEGN) as of Q1 2024, down from 206 in Q4 2023.
- Funds reported $4.85B of Legend Biotech stock for Q1 2024, down 6% quarter-over-quarter.
- 26 funds opened new Legend Biotech positions in Q1 2024 and 38 closed out, a net change of -12 holders.
- The largest Legend Biotech buyer in Q1 2024 was Fidelity Investments, an estimated $202M added.
- The largest Legend Biotech seller in Q1 2024 was Polar Capital Holdings, an estimated $73.2M sold.
Based on aggregated 13F filings for Q1 2024.